Process Parameter Development for the Scaled Generation of Stem Cell-Derived Pancreatic Endocrine Cells
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Diabetes is a debilitating disease characterized by high blood glucose levels. The global prevalence of this disease has been projected to reach 700 million adults by the year 2045. Type 1 diabetes represents about 10% of the reported cases of diabetes. Although islet transplantation can be a highly effective method to treat type 1 diabetes, its widespread application is limited by the paucity of cadaveric donor islets. The use of pluripotent stem cells as an unlimited cell source to generate insulin-producing cells for implant is a promising alternative for treating diabetes. However, to be clinically relevant, it is necessary to manufacture these stem cell-derived cells at sufficient scales. Significant advances have been made in differentiation protocols used to generate stem cell-derived cells capable of reversing diabetes in animal models and for testing in clinical trials. We discuss the potential of both stem cell-derived pancreatic progenitors and more matured insulin-producing cells to treat diabetes. We discuss the need for rigorous bioprocess parameter optimization and identify some critical process parameters and strategies that may influence the critical quality attributes of the cells with the goal of facilitating scalable manufacturing of human pluripotent stem cell-derived pancreatic endocrine cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on these requirements, approximately a billion SC-derived islet cells would be necessary to attain glycemic control and insulin independence26.”
From Scale up manufacturing approach for production of human induced pluripotent stem cell-derived islets using Vertical Wheel® bioreactors (2025) · cites this paper as [26]
In the citing paper
“Additionally, substantial cell loss occurs during the terminal stages of islet differentiation, with risk of unwanted off-target cells and cellular heterogeneity in the final product26,31.”
From Scale up manufacturing approach for production of human induced pluripotent stem cell-derived islets using Vertical Wheel® bioreactors (2025) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A ROCK inhibitor permits survival of dissociated human embryonic stem cells
Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T., Takahashi, J. B., Nishikawa, S., Nishikawa, S.-I., Muguruma, K., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1310 · Cited by 2,055 · cited 4×
“production because of the low efficiency of aggregate formation from single cells due to anoikis.(62,63) Significant cell losses have also been reported between 24 and 48 hours post aggregate formation.”
BackgroundResultInfluentialGeneration of Functional Human Pancreatic β Cells In Vitro
Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., & Melton, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.040 · Cited by 2,025
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843 · cited 2×
“developing differentiation protocols that yield functionally mature insulin-producing cells.(9,12,24-29) In some cases, PSC-derived insulinproducing cells generated entirely in vitro were capable of glucosestimulated insulin secretion(9,24-26,30) as well as increased calcium signaling and mitochondrial respiration, si…”
BackgroundEfficient differentiation of human embryonic stem cells to definitive endoderm
D'Amour, K. A., Agulnick, A. D., Eliazer, S., Kelly, O. G., Kroon, E., & Baetge, E. E. (2005) · Nature Biotechnology · doi:10.1038/nbt1163 · Cited by 1,730
Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells
Rezania, A., Bruin, J. E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3033 · Cited by 1,575
Self-citationPrevalence and prevention of cardiovascular disease and diabetes mellitus
Balakumar, P., Maung-U, K., & Jagadeesh, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.040 · Cited by 663 · cited 1×
“Diabetes is ranked within the top 10 most deadly diseases worldwide.(1,2)”
BackgroundRezania, A., Bruin, J. E., Riedel, M. J., Mojibian, M., Asadi, A., Xu, J., Gauvin, R., Narayan, K., Karanu, F., O’Neil, J. J., et al. (2012) · Diabetes · doi:10.2337/db11-1711 · Cited by 582 · cited 2×
“ters using cell culture platforms such as spinner flasks, low attachment six-well plates or air-liquid interface (Figure 3).(9,17,75) After that, the cell clusters may be further differentiated using static or dynamic 3D culture”
BackgroundMethodSelf-citationCharting cellular identity during human in vitro β-cell differentiation
Veres, A., Faust, A. L., Bushnell, H. L., Engquist, E. N., Kenty, J. H.-R., Harb, G., Poh, Y.-C., Sintov, E., Gürtler, M., Pagliuca, F. W., et al. (2019) · Nature · doi:10.1038/s41586-019-1168-5 · Cited by 552
Nair, G. G., Liu, J. S., Russ, H. A., Tran, S., Saxton, M. S., Chen, R., Juang, C., Li, M.-L., Nguyen, V. Q., Giacometti, S., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0271-4 · Cited by 472 · cited 7×
“A recent study showed that human PSC-derived insulin-producing cells and isolated human islets had a similar oxygen consumption rate (OCR) when challenged with high glucose.(24) In contrast, PSC-derived pancreatic progenitors have a lower OCR compared with human islets.”
BackgroundMethodInfluentialAcquisition of Dynamic Function in Human Stem Cell-Derived β Cells
Velazco-Cruz, L., Song, J., Maxwell, K. G., Goedegebuure, M. M., Augsornworawat, P., Hogrebe, N. J., & Millman, J. R. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.12.012 · Cited by 399 · cited 4×
“Many differentiation protocols used to make insulin-producing cells are initiated with 3D PSC aggregates (Figure 3).(18,24,25,60,61) After TABLE 1 An example of the quality-by-design process for the generation of pluripotent stem cell (PSC)-derived insulin-producing cells.”
BackgroundMethodInfluential
Research works printed but not linked: 77
- IDF, 2019, IDF Diabetes Atlas 9th edition 2019
- Bommer, 2018, Global economic burden of diabetes in adults: projections from 2015 to 2030, Diabetes Care, 41, 963, 10.2337/dc17-1962 · DOI · Paper page
- Bliss, 1982, Banting's, Best's and Collip's accounts of the discovery of insulin, Bull Hist Med, 56, 554
- Shapiro, 2000, Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen, N Engl J Med, 343, 230, 10.1056/NEJM200007273430401 · DOI · Paper page
- Andres, 2016, Clinical islet isolation and transplantation outcomes with deceased cardiac death donors are similar to neurological determination of death donors, Transpl Int, 29, 34, 10.1111/tri.12650 · doi:10.1111/tri.12650
- Markmann, 2003, The use of non-heart-beating donors for isolated pancreatic islet transplantation, Transplantation, 75, 1423, 10.1097/01.TP.0000061119.32575.F4 · DOI · Paper page
- D'Amour, 2006, Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells, Nat Biotechnol, 24, 1392, 10.1038/nbt1259 · DOI · Paper page
- Henry, 2018, Initial clinical evaluation of VC-01TM combination product—a stem cell–derived islet replacement for type 1 diabetes (T1D), Diabetes, 67, 10.2337/db18-138-OR · DOI · Paper page
- Pullen, 2018, Cell-derived pancreatic progenitor cells have now been transplanted into patients: report from IPITA 2018, Am J Transplant, 18, 1581, 10.1111/ajt.14954 · DOI · Paper page
- Keymeulen, 2021, 196-LB: stem cell-derived islet replacement therapy (VC-02) demonstrates production of C-peptide in patients with type 1 diabetes (T1D) and hypoglycemia unawareness, Diabetes, 70, 10.2337/db21-196-LB · DOI
- Schulz, 2012, A scalable system for production of functional pancreatic progenitors from human embryonic stem cells, PLoS One, 7, 10.1371/journal.pone.0037004 · DOI · Paper page
- Saber, 2018, Sex differences in maturation of human embryonic stem cell–derived β cells in mice, Endocrinology, 159, 1827, 10.1210/en.2018-00048 · DOI · Paper page
- Bruin, 2016, Hypothyroidism impairs human stem cell-derived pancreatic progenitor cell maturation in mice, Diabetes, 65, 1297, 10.2337/db15-1439 · DOI · Paper page
- Bruin, 2015, Accelerated maturation of human stem cell-derived pancreatic progenitor cells into insulin-secreting cells in immunodeficient rats relative to mice, Stem Cell Rep, 5, 1081, 10.1016/j.stemcr.2015.10.013 · DOI · Paper page
- Millman, 2016, Generation of stem cell-derived β-cells from patients with type 1 diabetes, Nat Commun, 7
- Wang, 2014, Differentiation of iPSCs into insulin-producing cells via adenoviral transfection of PDX-1, NeuroD1 and MafA, Diabetes Res Clin Pract, 104, 383, 10.1016/j.diabres.2014.03.017 · DOI
- Saxena, 2016, A programmable synthetic lineage-control network that differentiates human IPSCs into glucose-sensitive insulin-secreting beta-like cells, Nat Commun, 7, 1, 10.1038/ncomms11247 · DOI
- Zhu, 2019, Targeted derivation of organotypic glucose- and GLP-1-responsive β cells prior to transplantation into diabetic recipients, Stem Cell Rep, 13, 307, 10.1016/j.stemcr.2019.07.006 · DOI
- Vertex Announces FDA, 2021, Clearance of investigational new drug (IND) application for VX-880, a novel cell therapy for the treatment of Type 1 diabetes (T1D) | Vertex Newsroom
- Shapiro, 2017, Clinical pancreatic islet transplantation, Nat Rev Endocrinol, 13, 268, 10.1038/nrendo.2016.178 · DOI · Paper page
- Docherty, 2007, Embryonic stem cell therapy for diabetes mellitus, Semin Cell Dev Biol, 18, 827, 10.1016/j.semcdb.2007.09.009 · DOI
- Lock, 2007, Stem/progenitor cell sources of insulin-producing cells for the treatment of diabetes, Tissue Eng, 13, 1399, 10.1089/ten.2007.0047 · DOI · Paper page
- Lipsitz, 2016, Quality cell therapy manufacturing by design, Nat Biotechnol, 34, 393, 10.1038/nbt.3525 · DOI · Paper page
- Witcher, 2020, Why controlling CQAs isn't good enough for gene cell therapies
- Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019 · DOI · Paper page
- Yu, 2007, Induced pluripotent stem cell lines derived from human somatic cells, Science (80-), 318, 1917, 10.1126/science.1151526 · DOI · Paper page
- Chin, 2009, Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures, Cell Stem Cell, 5, 111, 10.1016/j.stem.2009.06.008 · DOI · Paper page
- Deng, 2009, Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming, Nat Biotechnol, 27, 353, 10.1038/nbt.1530 · DOI · Paper page
- Kim, 2011, Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells, Nat Biotechnol, 29, 1117, 10.1038/nbt.2052 · DOI · Paper page
- Yamanaka, 2012, Induced pluripotent stem cells: past, present, and future, Cell Stem Cell, 10, 678, 10.1016/j.stem.2012.05.005 · DOI · Paper page
- Moradi, 2019, Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations, Stem Cell Res Ther, 10, 1, 10.1186/s13287-019-1455-y · DOI · Paper page
- Stevens, 2018, Human pluripotent stem cell-derived engineered tissues: clinical considerations, Cell Stem Cell, 22, 294, 10.1016/j.stem.2018.01.015 · DOI · Paper page
- Stacey, 2019, Stem cell culture conditions and stability: a joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform, Regen Med, 14, 243, 10.2217/rme-2019-0001 · DOI
- 2007, Why do scientists need many lines of embryonic stem cells?, Nat Rep Stem Cells
- Beers, 2012, Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions, Nat Protoc, 7, 2029, 10.1038/nprot.2012.130 · DOI · Paper page
- Zakrzewski, 2019, Stem cells: past, present, and future, Stem Cell Res Ther, 10, 1, 10.1186/s13287-019-1165-5 · DOI · Paper page
- Bai, 2015, Temporal analysis of genome alterations induced by single-cell passaging in human embryonic stem cells, Stem Cells Dev, 24, 653, 10.1089/scd.2014.0292 · DOI · Paper page
- Borys, 2021, Overcoming bioprocess bottlenecks in the large-scale expansion of high-quality hiPSC aggregates in vertical-wheel stirred suspension bioreactors, Stem Cell Res Ther, 12, 55, 10.1186/s13287-020-02109-4 · DOI · Paper page
- Cruvinel, 2020, Long-term single-cell passaging of human iPSC fully supports pluripotency and high-efficient trilineage differentiation capacity, SAGE open Med, 8, 10.1177/2050312120966456 · DOI
- Thomson, 2008, Human embryonic stem cells passaged using enzymatic methods retain a normal karyotype and express CD30, Cloning Stem Cells, 10, 89, 10.1089/clo.2007.0072 · DOI
- Manstein, 2021, High density bioprocessing of human pluripotent stem cells by metabolic control and in silico modeling, Stem Cells Translational Medicine, 10, 1063, 10.1002/sctm.20-0453 · DOI · Paper page
- Sahabian, 2021, Production and cryopreservation of definitive endoderm from human pluripotent stem cells under defined and scalable culture conditions, Nat Protoc, 16, 1581, 10.1038/s41596-020-00470-5 · DOI
- Chen, 2010, Actin-myosin contractility is responsible for thcelle reduced viability of dissociated human embryonic stem cells, Cell Stem Cell, 7, 240, 10.1016/j.stem.2010.06.017 · DOI · Paper page
- Lipsitz, 2018, Chemically controlled aggregation of pluripotent stem cells, Biotechnol Bioeng, 115, 2061, 10.1002/bit.26719 · DOI · Paper page
- Chen, 2021, A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells, Nat Methods, 18, 528, 10.1038/s41592-021-01126-2 · DOI · Paper page
- Komatsu, 2017, Oxygen environment and islet size are the primary limiting factors of isolated pancreatic islet survival, PLoS One, 12, e0183780, 10.1371/journal.pone.0183780 · DOI · Paper page
- Sachlos, 2008, Embryoid body morphology influences diffusive transport of inductive biochemicals: a strategy for stem cell differentiation, Biomaterials, 29, 4471, 10.1016/j.biomaterials.2008.08.012 · DOI
- Nath, 2017, Size- and time-dependent growth properties of human induced pluripotent stem cells in the culture of single aggregate, J Biosci Bioeng, 124, 469, 10.1016/j.jbiosc.2017.05.006 · DOI
- Kato, 2018, Comparison of growth kinetics between static and dynamic cultures of human induced pluripotent stem cells, J Biosci Bioeng, 125, 736, 10.1016/j.jbiosc.2018.01.002 · DOI
- Kim, 2018, Adv Exper Med and Bio, 19
- Kim, 2018, Role of cell-secreted extracellular matrix formation in aggregate formation and stability of human induced pluripotent stem cells in suspension culture, J Biosci Bioeng, 127, 372, 10.1016/j.jbiosc.2018.08.010 · DOI
- Nogueira, 2019, Strategies for the expansion of human induced pluripotent stem cells as aggregates in single-use Vertical-Wheel™ bioreactors, J Biol Eng, 13, 1, 10.1186/s13036-019-0204-1 · DOI · Paper page
- Toyoda, 2015, Cell aggregation optimizes the differentiation of human ESCs and iPSCs into pancreatic bud-like progenitor cells, Stem Cell Res, 14, 185, 10.1016/j.scr.2015.01.007 · DOI · Paper page
- Pipeleers, 1985, Interplay of nutrients and hormones in the regulation of insulin release, Endocrinology, 117, 824, 10.1210/endo-117-3-824 · DOI · Paper page
- Holz, 1993, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37), Nature, 361, 362, 10.1038/361362a0 · DOI · Paper page
- Capozzi, 2019, β-Cell tone is defined by proglucagon peptides through cyclic AMP signaling, JCI Insight, 4, e126742, 10.1172/jci.insight.126742 · DOI · Paper page
- Svendsen, 2018, Insulin secretion depends on intra-islet glucagon signaling, Cell Rep, 25, 1127, 10.1016/j.celrep.2018.10.018 · DOI · Paper page
- Chowdhury, 2013, Functional differences between aggregated and dispersed insulin-producing cells, Diabetologia, 56, 1557, 10.1007/s00125-013-2903-3 · DOI · Paper page
- King, 2007, Normal relationship of beta- and non-beta-cells not needed for successful islet transplantation, Diabetes, 56, 2312, 10.2337/db07-0191 · DOI · Paper page
- Pipeleers, 1991, Transplantation of purified islet cells in diabetic rats: I. Standardization of islet cell grafts, Diabetes, 40, 908, 10.2337/diab.40.7.908 · doi:10.2337/diab.40.7.908
- Kieffer, 2016, Closing in on mass production of mature human beta cells, Cell Stem Cell, 18, 699, 10.1016/j.stem.2016.05.014 · DOI
- Ionescu-Tirgoviste, 2015, A 3D map of the islet routes throughout the healthy human pancreas, Sci Rep, 5, 10.1038/srep14634 · DOI · Paper page
- Kim, 2009, Islet architecture: a comparative study, Islets, 1, 129, 10.4161/isl.1.2.9480 · DOI · Paper page
- Lehmann, 2007, Superiority of small islets in human islet transplantation, Diabetes, 56, 594, 10.2337/db06-0779 · DOI · Paper page
- Macgregor, 2006, Small rat islets are superior to large islets in in vitro function and in transplantation outcomes Rat Islet Isolation and Separation Procedures, Am J Physiol Endocrinol Metab, 290, 771, 10.1152/ajpendo.00097.2005 · DOI · Paper page
- Fujita, 2011, Large human islets secrete less insulin per islet equivalent than smaller islets in vitro, Islets, 3, 1, 10.4161/isl.3.1.14131 · DOI
- Su, 2010, Small islets are essential for successful intraportal transplantation in a diabetes mouse model, Scand J Immunol, 72, 504, 10.1111/j.1365-3083.2010.02466.x · DOI
- Farhat, 2013, Small human islets comprised of more β-cells with higher insulin content than large islets, Islets, 5, 87, 10.4161/isl.24780 · DOI
- Yu, 2018, Bioengineered human pseudoislets form efficiently from donated tissue, compare favourably with native islets in vitro and restore normoglycaemia in mice, Diabetologia, 61, 2016, 10.1007/s00125-018-4672-5 · DOI · Paper page
- Ichihara, 2016, Size effect of engineered islets prepared using microfabricated wells on islet cell function and arrangement, Heliyon, 2, 10.1016/j.heliyon.2016.e00129 · DOI
- Cogger, 2017, Glycoprotein 2 is a specific cell surface marker of human pancreatic progenitors, Nat Commun, 8, 331, 10.1038/s41467-017-00561-0 · DOI · Paper page
- Ameri, 2017, Efficient generation of glucose-responsive beta cells from isolated GP2+ human pancreatic progenitors, Cell Rep, 19, 36, 10.1016/j.celrep.2017.03.032 · DOI · Paper page
- Stock, 2019, Conformal coating of stem cell-derived islets for β cell replacement in type 1 diabetes, Stem Cell Rep, 14, 91, 10.1016/j.stemcr.2019.11.004 · DOI · Paper page
- Bandeiras, 2019, Bringing stem cell-based therapies for type 1 diabetes to the clinic: early insights from bioprocess economics and cost-effectiveness analysis, Biotechnol J, 14, 10.1002/biot.201800563 · DOI
- Archibald, 2015, Using the cost-effectiveness of allogeneic islet transplantation to inform induced pluripotent stem cell-derived β-cell therapy reimbursement, Regen Med, 10, 959, 10.2217/rme.15.59 · DOI
- Bandeiras, 2019, Economics of beta-cell replacement therapy, Curr Diab Rep, 19, 1, 10.1007/s11892-019-1203-9 · DOI
- Iworima, 2021, Process parameter development for the scaled generation of stem cell-derived pancreatic endocrine cells, STEM CELLS Transl Med, 10, 1459, 10.1002/sctm.21-0161
Cited by
Ramzy, A., Thompson, D. M., Ward-Hartstonge, K. A., Ivison, S., Cook, L., Garcia, R. V., Loyal, J., Kim, P. T. W., Warnock, G. L., Levings, M. K., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.10.003 · Cited by 342
Self-citationDadheech, N., Bermúdez de León, M., Czarnecka, Z., Cuesta-Gomez, N., Jasra, I. T., Pawlick, R., Marfil-Garza, B., Sapkota, S., Verhoeff, K., Razavy, H., et al. (2025) · npj Regenerative Medicine · doi:10.1038/s41536-025-00409-y · Cited by 23
Yehya, H., Wells, A., Majcher, M., Nakhwa, D., King, R., Senturk, F., Padmanabhan, R., Jensen, J., & Bukys, M. A. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03973-0 · Cited by 7
Advances in Islet Transplantation and the Future of Stem Cell–Derived Islets to Treat Diabetes
Kieffer, T. J., Hoesli, C. A., & Shapiro, A. M. J. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041624 · Cited by 7
Self-citation
Metadata
- Authors
- Iworima, D. G., Rieck, S., & Kieffer, T. J.
- Venue
- Stem Cells Translational Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-08-13
- Volume
- 10
- Issue
- 11
- Pages
- 1459-1469
- ISSN
- 2157-6564
- 2157-6580
- Cited by
- 18
- References
- 22
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0/ (vor, 172 d)
- creativecommons.org/licenses/by/4.0/ (vor)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.